Takeyama Natsumi, Yuki Yoshikazu, Kiyono Hiroshi
Research Department, The University of Tokyo.
Nihon Rinsho. 2011 Sep;69(9):1555-60.
Mucosal vaccination has several advantages compared with that of injection-type vaccination. Secretory IgA(SIgA) produced at mucosal surface plays a key role for inactivation of toxins and inhibition of pathogen invasion. Although oral or nasal vaccination with attenuated live microorganisms have been shown to be effective in the induction of protective immunity, these types of vaccine have the ability to infect transiently to the host. For the development of safe and effective mucosal vaccine, an obvious strategy is the preparation of inactivated subunit-type mucosal vaccine. Here we introduce our frontier technology for the development of rice-based oral vaccines, as a new generation of mucosal vaccine. Further, we also discuss recent progress in the development of other types of mucosal vaccine and adjuvant.
与注射式疫苗接种相比，黏膜疫苗接种有几个优点。在黏膜表面产生的分泌型免疫球蛋白A（SIgA）在毒素灭活和病原体入侵抑制方面起关键作用。尽管用减毒活微生物进行口服或鼻内疫苗接种已被证明在诱导保护性免疫方面有效，但这类疫苗有短暂感染宿主的能力。为了开发安全有效的黏膜疫苗，一个明显的策略是制备灭活亚单位型黏膜疫苗。在此，我们介绍我们开发基于水稻的口服疫苗的前沿技术，作为新一代黏膜疫苗。此外，我们还讨论了其他类型黏膜疫苗和佐剂开发的最新进展。
